Kendra R. Adams's most recent trade in C4 Therapeutics Inc was a trade of 6,250 Common Stock done . Disclosure was reported to the exchange on Sept. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Kendra R. Adams | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2025 | 6,250 | 165,117 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Kendra R. Adams | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.32 per share. | 18 Sep 2025 | 2,775 | 162,342 | - | 3.3 | 9,213 | Common Stock |
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 130,600 | 130,600 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 87,100 | 169,676 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 4,559 | 165,117 | - | 3.2 | 14,498 | Common Stock |
| C4 Therapeutics Inc | Kendra Adams R. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,863 | 82,576 | - | 3.2 | 5,962 | Common Stock |